Can Vemurafenib cure melanoma?

Vemurafenib (Vemurafenib) is a targeted therapy that shrinks tumors and helps patients with advanced melanoma live longer. Vemurafenib induced responses in approximately 50% of patients with metastatic BRAF-mutant melanoma and demonstrated improved overall survival in a randomized phase III trial. In addition, vemurafenib is well tolerated, has low toxicity, and has a rapid onset of action. Vemurafenib is effective even in patients with extensive metastases.

Vemurafenib does not cure melanoma; it only slows the progression of the disease and improves patient survival. Targeted therapy is a cancer treatment that targets specific molecules within cancer cells. These drugs slow the growth and spread of cancer, such as melanoma, by blocking the function of abnormal molecules. Despite vemurafenib's success in treating patients with BRAF-mutated metastatic melanoma, most, if not all, patients eventually develop resistance, leading to disease progression in a median time of approximately 6 months. Vemurafenib also has some side effects, such as skin inflammation, nausea, vomiting, diarrhea, etc., and needs to be used under the supervision of a doctor.

Vemurafenib The original drug has been launched in China and has entered the scope of medical insurance. The price of 240mg*56 tablets per box may be around 7,000 yuan, which is very expensive. The Turkish version of Vemurafenib Original drug listed overseas, specifications240mg*56 tablets, may cost more than 2,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively cheap. There is currently no generic version of Vemurafenib on the market. For more drug information and specific prices, please consult a medical consultant.